Shares of Clearmind Medicine Inc. (CMND) surged over 70% on Monday morning after reporting encouraging clinical data.
The stock is currently trading at $1.23, up $0.51 or 70.02%, on the Nasdaq. It opened at $1.33 after closing the previous session at $0.72. The stock has traded between $0.59 and $52.40 over the past 52 weeks.
Clearmind said its CMND-100 drug candidate met the primary safety endpoint in a Phase I/IIa trial for Alcohol Use Disorder (AUD).
The treatment showed strong tolerability with no serious adverse events, supporting further development.
The results boost confidence in its non-hallucinogenic psychedelic-based therapy pipeline.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.